Patients presenting for TAVR or M-TEER with baseline moderate or severe tricuspid regurgitation were associated with lower post-treatment KCCQ scores and a higher mortality rate. Perhaps treating more of these patients with tricuspid valve repair or replacement could make a difference, researchers noted. 

The findings, based on data from more than 800 TAVR patients, suggest that skipping OAC medications for a small amount of time could make a big impact.

“No clear recommendation currently exists in U.S. or European guidelines for performing PCI in addition to TAVR,” researchers wrote. The group hoped its study could provide some clarity. 

The study, presented at ESC Congress 2024 in London, confirmed that TAVR was associated with significantly better outcomes than surgery when treating female patients. 

Complications are also down after SAVR, researchers noted, though the drop has been much more dramatic for TAVR patients. The new analysis was based on Medicare data from more than 210,000 patients.

ESC's annual meeting is always one of the world's largest gatherings of cardiologists and other cardiology professionals. This year's 4-day event will be no different. 

The self-expanding Acurate Prime Aortic Valve System was designed with improved valve positioning in mind. According to Boston Scientific, it it will be available in more sizes than the company's previous TAVR device to ensure it can treat as many heart patients as possible. 

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more.